Coronavirus patients recover in South Korea after plasma therapy
"Plasma therapy has its side effects and there has yet to be a large-scale clinical trial"
Two South Korean patients infected with Covid-19 have recovered after plasma treatments.
The doctors at Severance Hospital in Shincheon had plasma of virus survivors injected into the two patients, reports The Korea Herald.
The two patients were in critical condition and both have since been declared free of the virus.
No side effects have been reported, the hospital said.
"Both patients showed improvements in inflammation and the number of lymphocytes, among others, after receiving plasma injection and treatment with steroids," said professor Choi Jun-young, who is also the chief of the Division of Infectious Diseases at Severance Hospital.
"Plasma therapy has its side effects and there has yet to be a large-scale clinical trial, so it lacks scientific evidence. But it can be an alternative, used jointly with steroid treatment, for critical virus patients who aren't seeing results from antiviral treatments," Jun-young added.
One of the patients, a 71-year-old surnamed Kim, received 500 milliliters of plasma in 12-hour intervals twice, along with a steroid treatment, from a male survivor who had been declared free from the virus more than two weeks prior. The patient was transferred to Severance Hospital after failing to make progress with anti-malaria and AIDS drugs elsewhere.
Kim showed symptoms of pneumonia in both the lungs in an X-ray test and had trouble breathing when he first arrived.
His C-reactive protein, which shows systemic inflammation, had also risen to more than 20 times normal levels.
The other patient, 67, also made a full recovery and has now returned home.
Health authorities said a guideline on plasma therapy is to be rolled out in the coming days,
Korea Centers for Disease Control (KCDC) Deputy Director Kwon Jun-wook said: "We are to apply the guideline crafted during MERS (Middle East respiratory syndrome). But in terms of the effectiveness of the treatment, there needs to be more analysis of clinical trials."